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To assess the role of insulin receptor (IR) substrate
(IRS)-2 in insulin action and resistance in the liver,
immortalized neonatal hepatocyte cell lines have been
generated from IRS-2/, IRS-2/, and wild-type mice.
These cells maintained the expression of the differenti-
ated liver markers albumin and carbamoyl phosphate
synthetase, as well as bear a high number of IRs. The
lack of IRS-2 did not result in enhanced IRS-1 tyrosine
phosphorylation or IRS-1–associated phosphatidylinosi-
tol (PI) 3-kinase activity on insulin stimulation. Total
insulin-induced PI 3-kinase activity was decreased by
50% in IRS-2/ hepatocytes, but the translocation of
PI-3,4,5-trisphosphate to the plasma membrane in these
cells was almost completely abolished. Downstream PI
3-kinase, activation of Akt, glycogen synthase kinase
(GSK)-3 ( and  isoforms), Foxo1, and atypical pro-
tein kinase C were blunted in insulin-stimulated IRS-
2/ cells. Reconstitution of IRS-2/ hepatocytes with
adenoviral IRS-2 restored activation of these pathways,
demonstrating that IRS-2 is essential for functional
insulin signaling in hepatocytes. Insulin induced a
marked glycogen synthase activity in wild-type and
heterozygous primary hepatocytes; interestingly, this
response was absent in IRS-2/ cells but was rescued
by infection with adenoviral IRS-2. Regarding glucone-
ogenesis, the induction of phosphoenolpyruvate car-
boxykinase and glucose 6-phosphatase by dibutyryl
cAMP and dexamethasone was observed in primary
hepatocytes of all genotypes. However, insulin was not
able to suppress gluconeogenic gene expression in pri-
mary hepatocytes lacking IRS-2, but when IRS-2 signal-
ing was reconstituted, these cells recovered this
response to insulin. Suppression of gluconeogenic gene
expression in IRS-2–deficient primary hepatocytes was
also restored by infection with dominant negative
256Foxo1. Diabetes 52:2239–2248, 2003
Type 2 diabetes is a complex metabolic diseasewith an environmental and genetic componentaffecting 5% of the population in Western soci-eties. The pathogenesis of type 2 diabetes in-
volves abnormalities in both insulin action and secretion
(1). At the molecular level, insulin resistance, the first
detectable defect in type 2 diabetes, correlates with im-
paired insulin signaling in peripheral tissues. The trans-
genic and knockout technology used to create animal
models of type 2 diabetes have had a major impact on the
assessment of the function of insulin signaling molecules
implicated in the regulation of glucose homeostasis in vivo
(2). The insulin receptor (IR) substrate (IRS) proteins 1
and 2 are key mediators of many responses in insulin
sensitive tissues, especially those that are associated with
somatic growth and carbohydrate metabolism (3). During
the past few years, knockout mice have been generated
that define the specific roles of these molecules (4–7).
IRS-1–deficient (IRS-1/) mice were growth retarded and
mildly insulin resistant but did not develop diabetes.
Rather, these mice developed -cell hyperplasia, resulting
in compensatory insulin secretion (4,5). The residual insu-
lin action in IRS-1/ mice led to the discovery of IRS-2 as
an alternative signaling protein (8,9). IRS-2/ mice devel-
oped diabetes as a result of severe insulin resistance
paired with -cell failure (6,7,10). Previous experiments
performed in peripheral tissues of IRS-1/ mice by Yam-
auchi et al. (11) suggested that IRS-2 could be a major
player in hepatic insulin action. These results have been
assessed by other groups and, taken together, suggest that
IRS-2 can compensate IRS-1 deficiency more effectively in
liver and -cells than in muscle or adipose tissues (12,13).
However, to what extent reduced IRS-2 contributes to
insulin resistance in the liver remains uncertain.
More recently, a kinase cascade that mediates the
posttranscriptional actions of insulin in liver and other
tissues has been defined (3,14). The cascade begins when
activation of the IR results in tyrosine phosphorylation of
IRS proteins (3). Then phosphorylated IRSs bind proteins
containing Src homology 2 domains, such as the p85
regulatory subunit of phosphatidylinositol (PI) 3-kinase
(15), which has a central role in the metabolic actions
elicited by insulin. Analysis of human subjects and animal
models has indicated the existence of a correlation be-
tween impaired activation of PI 3-kinase in insulin target
tissues and insulin resistance in vivo (16–18). Downstream
from PI 3-kinase, the serine/threonine kinase Akt triggers
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insulin effects on the liver, such as glycogen synthesis and
the suppression of hepatic glucose production. One mech-
anism by which Akt might contribute to the insulin-
mediated suppression of glycogenolysis is by driving
glycogen synthesis through the activation of glycogen
synthase (GS). It has been demonstrated extensively that
an Akt-mediated inactivation of GS kinase (GSK)-3 con-
tributes to a reduction in the net phosphorylation and,
subsequently, activation of GS (19). Nonetheless, the ab-
solute contribution of Akt to the regulation of GS remains
uncertain because several signaling molecules not
influenced by Akt also modulate this process. Regarding
gluconeogenesis, the ability of insulin to suppress PEPCK
transcription is sensitive to PI 3-kinase inhibition (20,21).
Attempts to elucidate the signaling pathways downstream
of PI 3-kinase that mediate inhibition of gluconeogenic
gene expression have produced conflicting results, as
these studies (22,23) have relied on the overexpression of
genes encoding constitutively active and inactive mutants.
In the present study, we have developed new tools to
study the molecular mechanisms of IRS-2–mediated he-
patic insulin resistance. To analyze IRS-2 signals, we have
generated immortalized neonatal hepatocytes from wild-
type, heterozygous, and IRS-2–deficient mice by means of
SV40 large tumor antigen (LTAg) retroviral gene transfer.
Using these cell lines, as well as primary hepatocytes
derived from those animals, we have demonstrated in vitro
that IRS-2 signaling, through Akt/GSK-3 ( and  isoforms)
and atypical protein kinase C (PKC) /, is essential in
triggering two major metabolic actions of insulin in the
liver, i.e., activation of glycogen synthesis and inhibition of
gluconeogenic gene expression.
RESEARCH DESIGN AND METHODS
Materials. FCS and culture media were obtained from Gibco (Gaithersburg,
MD). Insulin and anti-mouse IgG-Agarose were obtained from Sigma Chemical
(St. Louis, MO). Protein A-Agarose was from Roche Molecular Biochemicals
(Mannheim, Germany). The anti–IRS-1 (06-248), anti–tyrosine phosphoryla-
tion (clone 4G10) (05-321), and anti–IRS-2 (06–506) antibodies were pur-
chased from Upstate Biotechnology (Lake Placid, NY). The anti–tyrosine
phosphate (Py20) (sc-508) and anti-PKC / (c-20) (sc-216) antibodies were
purchased from Santa Cruz Biotechnology (Palo Alto, CA). The anti–phospho
Akt (Ser473 no. 9271), anti–phospho p70s6k (Ser424/Thr421 no. 9204), anti-
Akt (no. 9272), anti-p70s6k (no. 9202), antiphospho GSK-3 / (’239331),
anti–phospho Foxo1 (serine256 ’239461), and anti-Foxo1 (’239462) antibodies
were purchased from Cell Signaling (Beverly, MA). For immunofluorescence,
fluorescein isothiocyanate (FITC)-conjugated sheep anti-mouse immuno-
globulins and monoclonal anti-vimentin (cloneV9) antibody were purchased
from Roche Molecular Biochemicals, polyclonal antialbumin antibody was
from Nordic Immunology Laboratories (Tilbury, the Netherlands), and mono-
clonal anti-CPS antibody was a gift from Dr. P. Martı´n-Sanz (Consejo Superior
de Investigaciones Cientificas, Madrid, Spain). Cy3-conjugated goat anti-rabbit
immunoglobulins, [32P]-ATP (3,000 Ci/mmol), [32P]-dCTP (3,000 Ci/mmol),
and 125I-labeled insulin (80 Ci/g) were from Amersham (Aylesbury, U.K.).
UDP-[U-14C] glucose was from NEN Chemicals. Immunofluorescence mount-
ing medium was from Vector (Burlingame, CA).
Cell culture and retroviral infections. Primary hepatocytes were obtained
from individual livers of 3.5- to 4-day-old neonatal mice from two to three
pregnant IRS-2/ mice mated with male IRS-2/ mice and further submitted
to collagenase dispersion and primary culture as previously described (24).
Viral Bosc-23 packaging cells were transfected at 70% confluence by calcium
phosphate coprecipitation with 3 g/6-cm dish of the puromycin-resistance
retroviral vector pBabe encoding SV40 LTAg (kindly provided by J. de Caprio,
Dana Farber Cancer Institute, Boston, MA). Then, neonatal hepatocytes were
infected at 60% confluence with polybrene (4 g/ml)-supplemented virus for
48 h and maintained in culture medium for 72 h, before selection with
puromycin (1 g/ml) for 1 week. One immortalized cell line from each animal
was generated and further cultured for 2–3 weeks with arginine-free medium
supplemented with 10% fetal bovine serum to avoid growth of nonparenchy-
mal cells.
Immunofluorescence and confocal imaging. Cells were grown in glass
coverslips until 80% confluence was reached. Cells were then washed twice
with PBS, fixed in methanol (20°C) for 2 min, and processed with immuno-
fluorescence. Primary antibodies (antialbumin, anti-CPS, and antivimentin)
were applied for 1 h at 37°C in PBS 1% BSA, followed by four 5-min washes in
PBS, a 45-min incubation with fluorescence-conjugated antibodies (FITC-
conjugated sheep anti-mouse and Cy3-conjugated goat anti-rabbit), and four
final washes of 5 min each in PBS. Immunofluorescence was examined with an
MRC-1024 confocal microscope (Bio-Rad, Hempstead, U.K.) adapted to an
inverted Nikon Eclipse TE 300 microscope. Images were taken with 488-nm
laser excitation for FITC-conjugated antibodies and 514-nm laser excitation
for Cy3-conjugated antibodies. Fluorescence emissions were detected
through a 513/24-nm bandpass filter for FITC and a 605/15-nm bandpass filter
for Cy3.
Transfection with the pleckstrin homology domain of general receptor
for phosphoinositides-1 domain–green fluorescent protein construct.
Cells were grown to 80% confluence and then transiently transfected with
8 g/6-cm dish of pleckstrin homology (PH) domain of general receptor for
phosphoinositides-1 domain (GRP1)-green fluorescent protein (GFP) cDNA
construct accordingly with the calcium phosphate–mediated protocol (Strat-
agene). Cells were serum starved for 4 h (24 h after transfection) and
subsequently stimulated with insulin (100 nmol/l) for 5 and 10 min. Cells were
then washed twice with PBS, fixed in methanol (20°C) for 2 min, and
processed with confocal immunofluorescence.
Transduction of IRS-2–deficient hepatocytes by adenoviral infec-
tion. Immortalized or primary hepatocytes were infected with 10 MOI
(multiplicity of infection or viral particles per cell) IRS-2 or 10 MOI mock
(-galactosidase). In other experiments, primary hepatocytes from IRS-2
knockout mice were infected with 10 MOI 	256Foxo1 mutant. Cells (80–90%
confluence) were routinely infected for 24–48 h, after which IRS-2–deficient
cells recovered IRS-2 expression. Then, cells were serum starved for 16–20 h
and subsequently used for further experiments.
Immunoprecipitations and Western blot. Quiescent cells (20 h serum
starved) were treated without or with several doses of insulin and lysed as
previously described (25). After protein content determination, equal amounts
of protein (500–600 g) were immunoprecipitated at 4°C with the corre-
sponding antibodies. The immune complexes were collected on protein
A-Agarose or anti-mouse IgG-Agarose beads and submitted to SDS-PAGE.
Proteins were transferred to Immobilon membranes and incubated overnight
with several antibodies as indicated. Immunoreactive bands were visualized
using the enhanced chemiluminescence Western blotting protocol (Amer-
sham).
PI 3-kinase activity. PI 3-kinase activity was measured in the anti–IRS-1,
anti–IRS-2, or anti–tyrosine phosphorylation immunoprecipitates by in vitro
phosphorylation of PI as previously described (25).
PKC / activity. Quiescent cells were treated for 10 min without or with
several doses of insulin and subsequently lysed. PKC / activity was
measured in anti-PKC / immunoprecipitates by an in vitro kinase assay as
previously described (25).
Measurement of GS activity. Cells were grown to confluence and then
serum starved for 20 h. Insulin (100 nmol/l) was added for 15 min, and control
cells were incubated in the absence of the hormone. After washing with PBS,
cells were scraped in 100 l GS assay buffer containing 100 mmol/l NaF, 35
mmol/l EDTA, and 0.5% glycogen (wt/vol) at pH 7.4. Cell lysates were then
sonicated three times for 3 s and centrifuged at 12,000g for 10 min at 4°C. The
clarified supernatants were aliquoted with GS assay buffer to equal protein
content. To measure GS activity, 20 l supernatant (6–8 g protein per l)
was added to 100 l GS activity buffer containing 72 mmol/l glycilglycine, 12%
glycogen (wt/vol), 12 mmol/l Na2SO4, and 0.3 mmol/l UDP-[U-
14C] glucose (0.1
Ci/tube) and then incubated for 15 min at 20°C. The reaction was stopped at
4°C by the addition of 200 l of 0.5N KOH, and after adding 35 l of 10%
glycogen (wt/vol) as carrier, the total glycogen was extracted by 2 ml ethanol
(66% final) over 30 min. The samples were centrifuged at 600g for 5 min, and
the precipitate was washed once with 5 ml of 66% ethanol and further
centrifuged at 3,000g for 30 min. The pellet was dissolved in water and
examined for its radioactive content in a scintillation counter. For total GS
activity, the reaction mixture included 7.2 mmol/l glucose 6-phosphate, and
Na2SO4 was omitted, as described (26).
Protein determination. Protein determination was performed by the Brad-
ford dye method (27), using the Bio-Rad reagent and BSA as the standard.
RNA extraction and Northern blot analysis. Primary hepatocytes were
isolated from individual livers and cultured to confluence. Cells were serum
starved for 20 h and further incubated for 6 h in the presence of 0.5 mmol/l
dibutyryl cAMP (dbcAMP) plus 1 mol/l dexamethasone) in either the
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absence or presence of insulin (100 nmol/l). In other experiments, cells were
infected with adenovirus as described above. Then, cells were serum starved
and further cultured for 6 h in the presence of 0.5 mmol/l dbcAMP plus 1
mol/l dexamethasone in either the absence or presence of insulin (100
nmol/l). At the end of the culture time, total RNA was isolated as described
(28) and submitted to Northern blot analysis. Blots were hybridized with
probes for PEPCK, glucose 6-phosphatase (G6Pase), and 18S ribosomal probe
to normalize RNA loading. Membranes were subjected to autoradiography,
and the relative densities of the hybridization signals were determined by
densitometric scanning of the autoradiograms.
Insulin binding. Cells cultured for 20 h in serum-free medium were incubated
for 3 h at 20°C with 0.03 nmol/l 125I-labeled insulin in 1 ml of binding buffer
containing 25 mmol/l HEPES/PBS, pH 7.4, and 1 mg/ml BSA in the absence or
presence of graded concentrations of unlabeled insulin. At the end of
incubation, monolayers were rinsed three times with ice-cold PBS/BSA and
then dissolved in 0.1 mol/l NaOH, 1% SDS, and 2% Na2CO3. Radioactivity was
counted by a Packard -counter. Nonspecific binding was defined as the
radioactivity that remained bound in the presence of a 1,000-fold excess of
unlabeled ligand. Bound/free plots and Scatchard plots were calculated for
triplicate dishes from three independent experiments.
RESULTS
Generation and characterization of immortalized
neonatal hepatocyte cell lines. Immortalized neonatal
hepatocyte cell lines were generated from individual livers
of wild-type (IRS-2/), heterozygous (IRS-2/), and IRS-
2–deficient (IRS-2/) mice. Hepatocytes were isolated
from single neonatal livers, and primary cultures were
prepared as previously described (24). All cell lines were
obtained after infection of neonatal hepatocytes in pri-
mary culture with retrovirus encoding LTAg, followed by
antibiotic (puromycin) selection for at least 3 weeks.
Then, immortalized cells were further cultured for 10–15
days in arginine-free medium supplemented with epider-
mal growth factor (20 ng/ml) to select hepatocytes with a
functional urea cycle. Then, we proceeded to characterize
the phenotype of these cell lines. For this purpose, we
performed immunofluorescence on growing cells with
antibodies against albumin and carbamoyl phosphate syn-
thetase (CPS). As shown in Fig. 1A, wild-type, IRS-2/,
and IRS-2/ neonatal hepatocytes express albumin (a
plasma protein secreted exclusively by hepatocytes) and
CPS (a urea cycle marker), indicating that after immortal-
ization these cells maintain hepatocyte phenotypic features.
Conversely, all cell lines showed negative immunofluores-
cence with the antivimentin antibody. Vimentin is a cy-
toskeletal marker characteristic to fibroblasts and should
be absent in parenchymal hepatocytes to confirm that the
maintenance of cell lines in arginine-free medium has
sufficiently eliminated possible contamination of fibro-
blasts in the primary culture. The expression of albumin
and CPS in all cell lines, regardless of the absence of IRS-2,
was also confirmed by Western blot analysis (Fig. 1B). In
addition, all cell lines showed similar levels of LTAg.
Western blot experiments revealed that immortalized
neonatal hepatocyte cell lines express IRS-2 protein at a
level consistent with the corresponding animal genotype,
with no IRS-2 being detected in IRS-2/ neonatal hepato-
cytes (Fig. 2A). Both wild-type and IRS-2/ hepatocytes
displayed a high number of high-affinity insulin binding
sites (303 
 103  33 
 103 sites/cell, Kd  66  9 nmol/l).
IR -chain expression (Fig. 2A) and its tyrosine phosphor-
ylation in response to insulin (results not shown) were
similar among the different cell lines analyzed. Thus, we
conclude that, based on these characteristics, immortal-
ized neonatal hepatocyte cell lines are insulin target cells.
To test whether the lack of IRS-2 was compensated by
IRS-1 as an alternative docking protein, quiescent cells
were stimulated with insulin (10–100 nmol/l) and total
protein was immunoprecipitated with anti–IRS-1 or IRS-2
antibodies and submitted to Western blot analysis with
anti–tyrosine phosphate antibody. Whereas IRS-2 tyrosine
phosphorylation was consistent with IRS-2 expression in
the three cell types, neither IRS-1 protein content nor its
tyrosine phosphorylation was increased in IRS-2–deficient
hepatocytes (Fig. 2B).
Effect of IRS-2 deficiency on the activation of PI
3-kinase and generation of PI(3,4,5) trisphosphate.
Next, we investigated the activation of PI 3-kinase, which
FIG. 1. Characterization of immortalized hepatocyte cell lines. A:
Immunofluorescence detection of albumin (Alb), CPS, and vimentin of
growing immortalized neonatal hepatocytes (wild-type, IRS-2/, and
IRS-2/). B: Cells were grown to confluence in the presence of 10%
fetal serum. Whole-cell lysates (50 g protein) were submitted to
SDS-PAGE and analyzed by Western blot using antibodies against
albumin, CPS, and LTAg. A representative experiment is shown.
FIG. 2. IR and IRS-1 and -2 expression and tyrosine phosphorylation in
immortalized wild-type, IRS-2/, and IRS-2/ neonatal hepatocytes.
A: Wild-type (IRS-2/), heterozygous (IRS-2/), and IRS-2–deficient
(IRS-2/) cells were grown to confluence in the presence of 10% fetal
serum. Whole-cell lysates (50 g protein) were analyzed by Western
blot using antibodies against IRS-2 and IR -chain. B: Quiescent (20-h
serum-starved) hepatocytes were stimulated with insulin (10–100
nmol/l) for 5 min. Control cells were cultured in the absence of the
hormone. At the end of the culture time, cells were lysed and 600 g of
total protein was immunoprecipitated with anti–IRS-1 and anti–IRS-2
antibodies. The resulting immune complexes were analyzed by Western
blotting with anti–tyrosine phosphate, anti–IRS-1, or anti–IRS-2 anti-
bodies, as indicated in each panel. The results shown are representa-
tive of three experiments.
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is involved in a number of metabolic actions of insulin in
immortalized neonatal hepatocyte cell lines. Quiescent
cells were stimulated with insulin (10–100 nmol/l), and
total cell lysates immunoprecipitated with antibodies
against IRS-1 and IRS-2 were immediately used for an in
vitro PI 3-kinase activity assay. Insulin stimulated IRS-2–
associated PI 3-kinase activity in wild-type and heterozy-
gous cells but not in IRS-2/ cells, which is consistent
with the IRS-2 protein levels in each cell line (Fig. 3). In
contrast, IRS-1–associated PI 3-kinase activity was similar
among the three cell types. To assess the relative contri-
butions of IRS-1 and IRS-2 to the total content of insulin-
stimulated PI 3-kinase activity, in vitro kinase reactions
were performed on anti–tyrosine phosphate immunopre-
cipitates. As shown in Fig. 3, the overall PI 3-kinase
activity decreased by 50% in IRS-2/ cells as compared
with that of wild-type. In addition, the ability of insulin to
stimulate the production of PI(3,4,5) trisphosphate (PIP3)
was determined by measuring the translocation of the PH
GRP1-GFP fusion protein in neonatal hepatocyte cell lines.
Several groups have reported that the PH domain of GRP1
specifically binds to PIP3 and acutely localizes in mem-
brane ruffles upon growth factor stimulation (29–31).
Whereas insulin stimulated the translocation of the PH
GRP1-GFP fusion protein to the membrane in 80% of
wild-type cells, only a small fraction of IRS-2–deficient
hepatocytes (10%) revealed membrane localization of
PH GRP1-GFP fusion protein in response to the hormone.
A representative experiment is shown in Fig. 4.
Differential activation of PI 3-kinase effectors in
wild-type, IRS-2/, and IRS-2/ neonatal hepato-
cytes. Downstream from PI 3-kinase, various serine/
FIG. 3. Insulin-stimulated PI 3-kinase activity in immortalized wild-type, IRS-2/, and IRS-2/ neonatal hepatocytes. Quiescent hepatocytes
were cultured and stimulated with insulin as described in Fig. 2B. At the end of the culture time, cells were lysed and 600 g total protein
immunoprecipitated with anti–IRS-1, anti–IRS-2, or anti–tyrosine phosphate antibodies and the resulting immune complexes were washed and
immediately used for an in vitro PI kinase assay. The conversion of PI to PIP in the presence of [	32-P]ATP was analyzed by thin-layer
chromatography. The origin of the thin-layer chromatography (Ori) and the migration of PIP are indicated by arrows. Representative
autoradiograms are shown. The autoradiograms corresponding to three independent experiments were quantitated by scanning densitometry.
Results are expressed as arbitrary units of PI 3-kinase and are means 
 SE.
FIG. 4. Differential effects of insulin on PIP3 production in wild-type
and IRS-2–deficient neonatal hepatocytes. Cells were grown to 80%
confluence and then transiently transfected with a plasmid encoding
PH GRP1-GFP fusion protein. After transfection (24 h), cells were
serum starved for 4 h and further stimulated with 100 nmol/l insulin for
5 and 10 min. Then, cells were washed twice with PBS, fixed in
methanol (20°C) for 2 min, and processed with confocal immunoflu-
orescence. A representative experiment is shown.
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threonine kinases become activated following insulin stim-
ulation. The Western blot demonstrated that insulin stim-
ulated Akt phosphorylation in wild-type immortalized
neonatal hepatocytes in a dose-dependent manner (Fig.
5A). This effect was slightly reduced in IRS-2/ cells and
severely impaired in IRS-2/ cells. Downstream from Akt,
both GSK-3 ( and  isoforms) and members of the
Forkhead family of transcription factors were phosphory-
lated and inactivated upon insulin treatment. Again, IRS-
2/ hepatocytes showed a reduced response to insulin in
GSK-3 phosphorylation (mainly GSK-3 isoform) and
Foxo1 (previously known as FKHR), as compared with
wild-type cells, but this effect was impaired in IRS-2/
cells. By contrast, serine/threonine phosphorylation of
p70s6k, another Akt target, was similar in the three cell
lines upon insulin stimulation, regardless of genotype.
Several studies performed in adipose tissue and skeletal
muscle suggest that activation of the atypical PKC iso-
forms ( and ) is required for insulin stimulation of
glucose uptake and GLUT4 translocation (32–34). To test
whether insulin activation of PKC / in the liver relies on
IRS-2/PI 3-kinase signaling, quiescent cells were stimu-
lated with insulin (10–100 nmol/l) for 10 min and PKC /
activity was determined by an in vitro protein kinase
assay. As shown in Fig. 5B, insulin increased PKC /
activity in wild-type hepatocytes, in which the response is
maximal at the 100-nmol/l concentration. Insulin activa-
tion of PKC / was not affected in cells lacking 50% IRS-2
expression (IRS-2/). However, insulin was unable to
activate PKC / in cells lacking IRS-2. The three cell types
showed similar PKC / protein content.
It has been proposed that phosphorylation of GSK-3
serves as a physiologically relevant mechanism for regu-
lating GS activity. Immortalized wild-type hepatocytes
displayed a substantial increase in GS activity upon insulin
stimulation (Fig. 5C). IRS-2/ cells responded similarly to
wild-type cells in the stimulation of GS activity. By con-
trast, the ability of insulin to activate GS in IRS-2/
hepatocytes was completely abolished.
Reconstitution of IRS-2 in immortalized hepatocytes
from IRS-2 knockout mice by adenoviral gene trans-
fer restores activation of Akt and PKC / and inac-
tivation of GSK-3 and Foxo1 by insulin. To test
whether the lack of IRS-2 is indeed responsible for im-
paired insulin signaling in IRS-2–deficient hepatocytes, we
reconstituted IRS-2 expression by adenoviral gene trans-
fer. Figure 6A reveals the re-expression of IRS-2 in two
different IRS-2/ hepatocyte cell lines. Following retrovi-
ral-mediated gene transfer, the level of IRS-2 expression
was similar to that detected in wild-type cells. Under these
FIG. 5. Differential effect of insulin on the activation of PI 3-kinase effectors in wild-type, IRS-2/, and IRS-2/ neonatal hepatocytes. A:
Quiescent (20-h serum-starved) wild-type (IRS-2/), IRS-2/, and IRS-2/ neonatal hepatocytes were stimulated with insulin (10–100 nmol/l)
for 5 min or maintained in the absence of the hormone. Cells were lysed, and total protein (50 g) was submitted to SDS-PAGE and analyzed by
immunoblotting with the corresponding antibodies against phospho-Akt, total Akt, phospho-p70s6k total p70s6k, phospho GSK3-(/),
phospho-Foxo1, and Foxo1. The autoradiograms corresponding to four independent experiments were quantitated by scanning densitometry. A
representative experiment is shown. B: Serum-starved hepatocytes were stimulated with insulin (10–100 nmol/l) for 10 min. Then cells were
lysed, and PKC / activity was determined as described in RESEARCH DESIGN AND METHODS. The autoradiograms corresponding to three independent
experiments were quantitated by scanning densitometry. Results are expressed as arbitrary units of myelin basic protein (MBP) phosphorylation
and are means 
 SE. C: Immortalized hepatocyte cell lines were grown to confluence and then serum starved for 20 h. Insulin (100 nmol/l) was
added for 15 min, and control cells were incubated in the absence of the hormone. GS activity was assayed in the supernatants of cell lysates as
described in RESEARCH DESIGN AND METHODS in the absence or presence of 10 mmol/l glucose 6-phosphate. GS activity is expressed as a percentage
of the basal nonstimulated values. Data are means 
 SE for six to eight different experiments.
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experimental conditions, we tested whether insulin signal-
ing downstream from PI 3-kinase could be recovered. As
shown in Fig. 6B, phosphorylation of Akt and its down-
stream targets, GSK-3 ( and  isoforms) and Foxo1, were
rescued in IRS-2 reconstituted hepatocytes (adenoviral
IRS-2), reaching levels comparable with those observed in
wild-type cells. Furthermore, activation of PKC / by
insulin was even higher in adenoviral-infected IRS-2–
deficient hepatocytes than in wild-type cells (Fig. 6C).
Insulin fails to activate GS and to inhibit PEPCK and
G6Pase mRNA expression in IRS-2–deficient primary
hepatocytes. To investigate whether the lack of IRS-2 in
hepatocytes could interfere with the metabolic actions of
insulin, we performed experiments in a more physiological
cellular model. Isolated hepatocytes from wild-type, het-
erozygous, and IRS-2 knockout neonates were cultured as
described in RESEARCH DESIGN AND METHODS. Then, GS activity
was measured in 20-h serum-deprived cells following 15
min of insulin stimulation. As shown in Fig. 7A, both
insulin-treated wild-type and heterozygous hepatocytes in
primary culture displayed an increase in GS activity. By
sharp contrast, insulin failed to activate GS in IRS-2/
primary hepatocytes.
Gluconeogenesis is a highly regulated process catalyzed
by several enzymes under the regulation of insulin. In vivo,
insulin resistance in the livers of IRS-2 knockout mice
appears to result from the failure of the hormone to inhibit
hepatic glucose production (HGP). In liver, PEPCK and
G6Pase are rate-limiting enzymes for gluconeogenesis.
Accordingly, our next step was to study in vitro whether
gluconeogenic enzymes were induced by an appropriated
stimulus (dexamethasone/cAMP) in primary cultures of
wild-type, IRS-2/, and IRS-1/ mouse neonatal hepato-
cytes. Hepatocytes isolated from single livers were grown
to confluence, and after 20 h of serum deprivation a
mixture of dexamethasone/cAMP was added to the me-
dium for a further 6 h. RNA was then isolated and analyzed
by Northern blot. As shown in Fig. 7B, both PEPCK and
G6Pase mRNA were induced by dexamethasone/cAMP in
the three cell types studied, regardless of IRS-2 expres-
sion. We studied the effect of insulin on gluconeogenic
gene expression. Insulin triggered a substantial inhibition
of dexamethasone/cAMP-induced PEPCK and G6Pase
mRNAs in wild-type and IRS-2/ hepatocytes but was
incapable of suppressing dexamethasone/cAMP-induced
gluconeogenic gene expression in primary hepatocytes
derived from IRS-2–deficient mice.
Reconstitution of IRS-2 signaling in primary cultures
of neonatal hepatocytes rescues activation of GS and
inhibition of gluconeogenic gene expression by insu-
lin. Given the failure of insulin to induce GS activity and to
suppress PEPCK and G6Pase mRNA expression in primary
IRS-2–deficient hepatocytes, we addressed whether the
reconstitution of IRS-2 signaling in these cells could
restore insulin sensitivity. IRS-2/ primary hepatocytes
were infected with adenoviral vectors encoding wild-type
IRS-2 and mock. After 24 h, cells were serum starved for a
further 16–20 h. Then, cells were stimulated with insulin
for 15 min, and GS activity was determined. As shown in
Fig. 8A, insulin stimulated GS activity in reconstituted
hepatocytes (adenoviral IRS-2) to a level similar to that
observed in wild-type cells. Insulin failed to activate GS in
mock-infected IRS-2–deficient cells. Next, we investigated
the ability of IRS-2 to mediate insulin-induced suppression
of gluconeogenic gene expression. Primary hepatocytes
were infected as indicated above. After 24 h of infection,
cells were serum starved for 4 h and then stimulated for
6 h with dexamethasone/cAMP in the absence or presence
of insulin (100 nmol/l). Figure 8B demonstrates that
PEPCK and G6Pase mRNA expression (induced by dexa-
FIG. 6. Reconstitution of IRS-2 expression and its signaling in IRS-2–deficient hepatocytes by adenoviral gene transfer. A: Immortalized
IRS-2–deficient neonatal hepatocytes were grown to confluence. Cells were then infected with adenovirus encoding wild-type IRS-2 and mock
(-galactosidase). After 24–48 h, cells were lysed, and IRS-2 expression in the different cell lines was assessed by Western blot. B: Cells were
infected with adenovirus encoding wild-type IRS-2 and mock (-galactosidase), as described in A. Then cells were serum starved for 16–20 h and
further stimulated with insulin (10–100 nmol/l) for 5 min. Phosphorylation of Akt, GSK-3, and Foxo1 was assessed by Western blot. A
representative experiment out of three is shown. C: Cells were infected and further stimulated with insulin as described above. PKC / activity
was determined in anti-PKC / immune complexes as described under RESEARCH DESIGN AND METHODS. The results from three independent
experiments were quantitated by scanning densitometry and are means 
 SE.
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methasone/cAMP) was significantly suppressed by insulin
in reconstituted IRS-2/ hepatocytes (adenoviral IRS-2)
compared with IRS-2/ hepatocytes, which lacked this
effect.
Finally, we investigated an alternative mechanism to
overcome insulin resistance in the gluconeogenic path-
ways of IRS-2–deficient hepatocytes. Nakae et al. (35)
have recently proposed that the truncated Foxo1 mutant
that lacks the transactivation domain (	256) could be a
useful reagent for inhibiting gluconeogenesis in experi-
mental systems. Accordingly, we tested this approach in
our in vitro model of IRS-2–deficient primary hepatocytes
by assessing the effect of 	256Foxo1 on gluconeogenic
gene expression. Transduction of IRS-2/ hepatocytes
with adenoviral vector encoding 	256Foxo1 mutant,
which competes with endogenous Foxo1 and exerts a
dominant negative effect, totally eliminated dexametha-
sone/cAMP-induced PEPCK and G6Pase mRNA expres-
sion in the absence of insulin (Fig. 8B).
DISCUSSION
Hepatic insulin resistance is a common feature of animal
models of insulin resistance and type 2 diabetes. IRS-2
knockout is a genetic mouse model with increased HGP
(6,7). In addition, ablation of IRS-2 results in an impaired
development of pancreatic -cells as a result of a lack of
IGF-I signaling (36). However, the combined defect of
-cell failure and peripheral insulin resistance has compli-
cated the analysis of hepatic insulin resistance as a pri-
mary cause of the type 2 diabetic phenotype of IRS-2–
deficient mice. In this study, we generated immortalized
hepatocyte cell lines derived from individual livers of
wild-type, heterozygous, and IRS-2 knockout mice. By
using this approach we attempted to define the role of
IRS-2 in the insulin-signaling network of hepatocytes and
relate signaling defects to the abnormalities in the hepatic
carbohydrate metabolism described in the IRS-2–deficient
mice. These cells provided an excellent tool for in vitro
study of insulin signaling leading to the expression of
genes implicated in liver glucose metabolism.
FIG. 7. Insulin failed to activate GS and inhibit dexamethasone/cAMP-
induced PEPCK and G6Pase gene expression in IRS-2–deficient pri-
mary neonatal hepatocytes. A: Primary hepatocytes obtained from
3-day-old mouse livers were cultured to confluence as described in
RESEARCH DESIGN AND METHODS and then serum starved for 20 h. Insulin
(100 nmol/l) was added for 15 min, and control cells were incubated in
the absence of the hormone. GS activity was assayed in the superna-
tants of cell lysates as described in RESEARCH DESIGN AND METHODS in the
absence or presence of 10 mmol/l glucose 6-phosphate. GS activity is
expressed as a percentage of the basal nonstimulated values. Data are
means 
 SE for six to eight different experiments. B: Primary hepato-
cytes were cultured to confluence. Then cells were serum starved for
20 h and further cultured for 6 h in the presence of 0.5 mmol/l dbcAMP
plus 1 mol/l dexamethasone in either the absence or presence of 100
nmol/l insulin. At the end of the culture, RNA was isolated, submitted
to Northern blot analysis, and hybridized with labeled PEPCK, G6Pase,
and 18S rRNA cDNA. Representative autoradiograms are shown.
FIG. 8. Reconstitution of IRS-2 in IRS-2–deficient neonatal primary
hepatocytes restores activation of GS and inhibition of gluconeogenic
gene expression by insulin. A: IRS-2–deficient primary hepatocytes
were infected with adenovirus encoding wild-type IRS-2 and mock
(-galactosidase) as described above. After infection (24 h), cells were
serum starved for 16–20 h and further stimulated with 100 nmol/l
insulin for 15 min. GS activity was assayed in the supernatants of cell
lysates as described in RESEARCH DESIGN AND METHODS in the absence or
presence of 10 mmol/l glucose 6-phosphate. GS activity is expressed as
a percentage of the basal nonstimulated values. Data are means 
 SE
for six to eight different experiments. B: Primary hepatocytes were
cultured to confluence as described in RESEARCH DESIGN AND METHODS.
Then cells were infected with adenoviral constructs encoding IRS-2,
256Foxo1, and mock (-galactosidase). After infection (24 h), cells
were serum starved for 4 h and further stimulated for 6 h in the
presence of 0.5 mmol/l dbcAMP plus 1 mol/l dexamethasone in either
the absence or presence of 100 nmol/l insulin. At the end of the culture
time, RNA was isolated and submitted to Northern blot analysis and
hybridized with labeled PEPCK, G6Pase, and 18S rRNA cDNA. Repre-
sentative autoradiograms are shown.
A.M. VALVERDE AND ASSOCIATES
DIABETES, VOL. 52, SEPTEMBER 2003 2245
The new hepatocyte cell lines (IRS-2/, IRS-2/, and
IRS-2/) were grown for at least 3 weeks in arginine-free
medium to select cells with a functional urea cycle. Under
these culture conditions, we circumvented the potential
contamination of the primary cultures with nonparenchy-
mal cells, such as fibroblasts, as assessed by negative
immunofluorescence with the antivimentin antibody. In
addition, all cell lines maintained the expression of albu-
min, a protein secreted by hepatocytes, and CPS, a urea
cycle enzyme marker. Moreover, the number of IRs and
their affinity were similar among the different cell types,
indicating that immortalized hepatocytes are insulin target
cells. In regard to insulin signaling, our experiments in
immortalized neonatal hepatocytes show that the lack of
IRS-2 is not compensated for by an elevation of IRS-1
protein content or an increase in tyrosine phosphoryla-
tion. Furthermore, whereas PI 3-kinase activity associated
with tyrosine phosphorylated proteins was reduced by 50%
in IRS-2/ hepatocyte cell lines, the IRS-1–associated PI
3-kinase was similar to the wild-type. These results are in
agreement with those previously reported in liver extracts
(7), thus strengthening the essential and specific role of
IRS-2 in mediating downstream signaling to PI 3-kinase in
the liver. Experiments performed in the muscle of IRS-
2/ animals, where total PI 3-kinase activity was unaf-
fected, support the concept of the tissue specificity of
insulin action, as well as the distinct compensatory mech-
anisms in the different insulin-responsive tissues (7,12).
The fact that only a small number of IRS-2/ hepato-
cytes (10%) translocate the PH GRP1-GFP fusion protein
to the membrane in response to insulin stimulation indi-
cates that the generation of plasma membrane PIP3 is
severely reduced in the absence of IRS-2. Consequently,
the phosphorylation of Akt and GSK-3 in IRS-2/ hepato-
cytes upon insulin stimulation was severely reduced com-
pared with that of wild-type. These results suggest that
IRS-2–associated PI 3-kinase activity may constitute the
main source of PIP3 in hepatocytes, given that IRS-1–
associated PI 3-kinase is unable to compensate this re-
sponse to insulin in IRS-2–/– cells. Furthermore, both Akt
and GSK-3 phosphorylation were recovered after reconsti-
tution of IRS-2 signaling in deficient cells. Again, these
data emphasize the tissue specificity of molecular defects
that contribute to insulin resistance. Conversely, activa-
tion of p70s6 kinase in immortalized hepatocytes was
unaffected by the lack of IRS-2. These results illustrate a
diverging signaling pathway downstream from PI 3-kinase
and further support the existence of alternative PI 3-ki-
nase–independent pathways that regulate the activation of
p70s6 kinase in the liver, thereby preventing inhibition of
protein synthesis (37). The fact that p70s6 kinase-1 knock-
out mice display a diabetic phenotype suggests a mecha-
nism of insulin resistance independent of IRS-2 (38).
Our results demonstrate that the alterations in insulin
signaling related to the lack of IRS-2 in hepatocytes have
important metabolic implications. Our studies reveal for
the first time that insulin fails to activate GS in vitro in
IRS-2/ hepatocytes, a response that can be recovered
after IRS-2 reconstitution. Since PI 3-kinase activity in the
liver is essential for normal function of carbohydrate and
lipid metabolism in living animals (39), our results might
be a direct consequence of the impaired Akt phosphory-
lation and GSK-3 inactivation in IRS-2/ hepatocytes. In
fact, previous experiments (40) in immortalized hepato-
cytes from IR knockout mice show that a selective loss of
IRS-2/PI 3-kinase signaling results in decreased glycogen
synthesis. However, the fact that insulin-induced PKC /
activity is also suppressed in the absence of IRS-2 and
further recovered after IRS-2 reconstitution indicates that
this molecule could participate in the phosphorylation and
inactivation of hepatic GS. Interestingly, it has been re-
cently reported that PKC  phosphorylates GSK-3  and 
isoforms in L6hIR cells, and this event is an essential
requirement for GS activation (41). In the light of these
results, an attractive therapeutic approach to ameliorate
hepatic insulin resistance in the absence of IRS-2 would be
the use of novel GSK-3 inhibitors, which could improve
glucose disposal through the enhancement of glycogen
synthesis in the liver (42).
The development of fasting hyperglycemia in type 2
diabetes is believed to be secondary to increased HGP,
mainly through an increase in gluconeogenic pathways.
The importance of the liver in the maintenance of normo-
glycemia has been studied through different approaches.
In mice overexpressing PEPCK or G6Pase, insulin is
unable to suppress HGP despite the presence of hyperin-
sulinemia (43,44). These findings prompted us to investi-
gate whether the alterations of IRS-2/PI 3-kinase signaling
in IRS-2/ hepatocytes could account for dysregulation in
gluconeogenic gene expression. We found that insulin
failed to inhibit dexamethasone/cAMP-induced PEPCK
and G6Pase mRNA in primary hepatocytes of IRS-2/
mice, but not in wild-type or heterozygous mice. More-
over, IRS-2 reconstitution of deficient hepatocytes led to a
full recovery of insulin inhibition in gluconeogenic gene
expression. Thus, our in vitro results indicate that the
metabolic changes in hepatic function in IRS-2–deficient
animals (45) could be the result of alterations in insulin
signaling that produce a dysregulation of gene expression.
Previous experiments (46) performed in liver-specific IR
knockout mice showed a substantial increase in gluconeo-
genic gene expression accompanied by an unexpected
FIG. 9. Role of IRS-2 in the insulin-signaling cascade in hepatocytes.
IRS-2–deficient neonatal hepatocytes showed insulin resistance in
reference to IRS-2/PI 3-kinase signaling. Downstream from PI 3-kinase,
insulin failed to activate Akt, GSK-3 ( and  isoforms), and PKC / in
the absence of IRS-2. At the nuclear level, the phosphorylation of
Foxo1 is also impaired. Insulin upregulated GS activity and downregu-
lated gluconeogenic gene expression in wild-type hepatocytes. The lack
of IRS-2 in hepatic cells resulted in the dysregulation of GS activation
and the inhibition of gluconeogenic gene expression.
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increase in IRS-2 protein content. More recently, it has
been reported (47) that PEPCK overexpression in the liver
results in a selective downregulation of IRS-2 expression
and a failure of insulin to suppress HGP. Taken together,
all of these data strongly suggest that IRS-2, PI 3-kinase,
and Akt signaling drive insulin-negative regulation of glu-
coneogenic gene expression. In addition, GSK-3 may also
regulate PEPCK and G6Pase gene expression in neonatal
hepatocytes through the phosphorylation and inactivation
of transcription factors such as CCAAT/enhancer-binding
protein- or cMP response element binding protein,
which have potent stimulatory effects on PEPCK gene
transcription (48).
The possibility of controlling hepatic glucose utilization
and production as a treatment of type 2 diabetes has been
explored by Ferre et al. (49) by overexpressing glucoki-
nase in the liver of diabetic mice. In the liver of these
animals, glycolysis and glycogen synthesis were induced
while gluconeogenesis was blocked, resulting in the nor-
malization of blood glucose levels. Therefore, this ap-
proach could be of potential interest in the treatment of
the hepatic insulin resistance that is developed in type 2
diabetes and is associated with the lack of IRS-2, and it
might circumvent the requirement of -cell compensatory
mechanisms. In a study related to therapies for ameliorat-
ing hepatic insulin resistance, Nakae et al. (35) found that
the dominant-negative Foxo1 mutant provides a useful
reagent for inhibiting gluconeogenesis in experimental
systems. In fact, they recently demonstrated that Foxo1
haploinsufficiency corrects hepatic insulin resistance in
IR/ diabetic mice (50). Foxo1 is phosphorylated in an
insulin-responsive manner by PIP3-dependent kinases,
such as Akt, and then excluded from the nucleus (51–53).
Studies in hepatoma cells (54,55) suggest that Foxo1 and
-3 regulate the transcription of reporter genes containing
insulin response elements from the PEPCK and G6Pase
promoters. More recently, insulin signaling via Akt to
Foxo1 has been shown to inhibit the expression of the
peroxisome proliferator–activated receptor- coactivator
(PGC-1) (56), which is induced in the liver in the fasting
state and in various mouse models with deficient insulin
action. It is also required for the expression of PEPCK and
G6Pase (57). In the current study, we demonstrate that
phosphorylation of Foxo1 by Akt relies on IRS-2 signaling
in neonatal hepatocytes and that the 	256Foxo1 domi-
nant-negative mutant rescues the insulin resistance ob-
served in IRS-2–deficient hepatocytes, thus restoring the
inhibition of PEPCK and G6Pase expression induced by
dexamethasone/cAMP in an insulin-independent manner.
Whether 	256Foxo1 directly blocks access to Foxo sites
in the PEPCK promoter or functions indirectly by blocking
the expression of coactivators such as PGC-1, which are
required for PEPCK expression, remains to be established.
These results reinforce the hypothesis that dominant-
negative Foxo1 could be of potential benefit in reducing
glucose production in diabetic patients. However, further
effects of this therapy on liver function need to be inves-
tigated extensively.
In conclusion, our results demonstrate the essential role
of IRS-2 in insulin-regulated glycogen synthesis and in the
expression of gluconeogenic enzymes involved in HGP, as
summarized in Fig. 9. The current studies, taken together
with the phenotype of the IRS-2 knockout model, impli-
cate IRS-2 as the principal mediator of insulin action in
liver and suggest that impaired IRS-2 signaling may repre-
sent a major component of liver insulin resistance.
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